23 citations
,
June 2018 in “Facial Plastic Surgery” This review suggests that platelet-rich plasma is a low-risk treatment for androgenic alopecia with good patient satisfaction and positive objective outcomes, but further research is needed to refine methods and standardize outcome measurements.
27 citations
,
July 2017 in “Facial Plastic Surgery” This review examines the growing evidence for using platelet-rich plasma in aesthetic procedures such as hair restoration and skin rejuvenation but reports no new clinical results.
70 citations
,
February 2017 in “Dermatologic Surgery” This study reports that plasma rich in growth factors appeared to improve hair follicle regeneration and patient satisfaction in individuals with androgenetic alopecia, though further trials are needed.
136 citations
,
February 2017 in “International Journal of Molecular Sciences” This study observed that autologous platelet-rich plasma treatment improved hair count and density in areas with androgenetic alopecia compared to placebo, with differing outcomes based on the PRP collection device used.
33 citations
,
January 2017 in “Journal of Cutaneous and Aesthetic Surgery” This study found that PRP injections improved hair density, quality, and thickness in males with androgenic alopecia compared to placebo, with reported high patient satisfaction and no major side effects.
3 citations
,
December 2016 in “Blood” This study found PRP treatment significantly increased hair count and anagen hairs in male patients with androgenetic alopecia, but there was no correlation between therapeutic response and platelet or growth factor levels.
60 citations
,
September 2016 in “Dermatologic Surgery” This article proposes a mechanistic model for how platelet-rich plasma therapy may stimulate hair growth in androgenetic alopecia by promoting vascularization and activating specific signaling pathways, but it reports no new experimental results.
87 citations
,
September 2016 in “Dermatologic Surgery” This study found that platelet-rich plasma did not significantly improve hair mass index or hair count in women with female androgenetic alopecia, though some patients perceived benefits in hair quality.
61 citations
,
September 2016 in “Journal of Cosmetic and Laser Therapy” This study found that platelet-rich plasma was not effective in treating androgenetic alopecia in men with grade 4–6 hair loss.
136 citations
,
April 2016 in “Dermatologic Surgery” This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.
106 citations
,
January 2016 in “Journal of Cosmetic Dermatology” This study found that adding platelet-rich plasma to microneedling improved outcomes for atrophic acne scars more than microneedling alone, according to both quantitative and qualitative assessments.
13 citations
,
January 2016 in “Journal of the Egyptian Women's Dermatologic Society (Print)” This abstract discusses platelet-rich plasma therapy for patterned hair loss but provides no new clinical results, suggesting further research is needed to determine its effectiveness.
214 citations
,
September 2015 in “Stem Cells Translational Medicine” This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.
66 citations
,
June 2015 in “Aesthetic Plastic Surgery” This review of 47 studies indicates that platelet preparations may significantly enhance cellular activity, wound healing, and facial aesthetic outcomes in facial plastic surgery, though potential publication bias should be considered.
25 citations
,
May 2014 in “Facial Plastic Surgery” In this study, intradermal injections of autologous platelet-rich fibrin matrix significantly increased hair density in patients with androgenetic alopecia at 2 and 3 months after initial treatment.
183 citations
,
January 2014 in “BioMed Research International” This study reported that AA-PRP injections significantly increased hair count and density in individuals with pattern hair loss compared to baseline, demonstrating their potential for enhancing hair growth.
115 citations
,
January 2014 in “Journal of Cutaneous and Aesthetic Surgery” In this study, PRP injections increased hair count and reduced hair loss in patients with androgenic alopecia not responding to minoxidil and finasteride, with high patient satisfaction reported.
164 citations
,
January 2014 in “Journal of Cutaneous and Aesthetic Surgery” This study found that PRP injections may improve hair density and reduce hair loss in patients with androgenetic alopecia without significant side effects, but further research is needed to confirm efficacy.
88 citations
,
December 2012 in “Journal of The European Academy of Dermatology and Venereology” This study found that interfollicular injection of autologous CD34+ cell-containing PRP preparation improved hair count and thickness in patients with pattern hair loss, with better results than placental extract treatment.
166 citations
,
August 2011 in “Dermatologic Surgery” This study found that PRP combined with dalteparin and protamine microparticles may enhance hair growth by increasing hair thickness compared to PRP alone.
41 citations
,
January 2009 in “International Journal of Trichology” This study found that 58% of men aged 30-50 had androgenic alopecia, with disease severity increasing with age and many being candidates for medical treatment or hair transplantation.
251 citations
,
October 2006 in “Plastic and reconstructive surgery/PSEF CD journals” In this study, platelet plasma growth factors from patients' autologous plasma improved follicular unit yield in baldness surgery by 15.1% compared to control areas.
193 citations
,
August 2005 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that the prevalence of androgenetic alopecia increases with age among both men and women in Maryborough, Australia, with 57% of women and 73.5% of men aged 80 and over affected.